Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe, North America, Latin America, Asia-Pacific, Middle East and Africa: 2,207 cases from 44 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by regionAll jurisdictions
What for?
by area of lawAll areas of law
Who?
by company- Anonymised companies €221.6m 39 % · 45 cases
- Becton, Dickinson and Company (BD) €166.7m 30 % · 1 case
- Access DX Laboratory, LLC €31.7m 6 % · 1 case
- Advanced Pathology Solutions PLLC und APS MSO LLC €25.9m 5 % · 1 case
- C.R. Bard, Inc.; Liberator Medical Supply, Inc.; Liberator Holdings; Rochester Medical Corporation €16.3m 3 % · 1 case
- NUWAY Alliance, Inc. €15.8m 3 % · 1 case
- Medirex s. r. o.; KLINICKÁ BIOCHÉMIA s.r.o.; Unilabs Slovensko, s. r. o.; synlab slovakia s. r. o.; Asociácia laboratórií €14.6m 3 % · 1 case
- Oroville Hospital €9.77m 2 % · 1 case
- NeoGenomics Laboratories Inc. €8.59m 2 % · 1 case
- PHOENIX Zdravotnícke zásobovanie, a.s.; TRANSMEDIC SLOVAKIA, s.r.o. (in Konkurs) €7.8m 1 % · 1 case
- 35 more€46.1m
When?
per year, by date of decision| Period | Cases | Total |
|---|---|---|
| 2026 | 1 | €31.7m |
1 case
30 Jul 2026 Access DX Laboratory, LLCAccess DX Laboratory: 36.4 million USD – kickbacks for unnecessary genetic tests €31.7m
The Houston laboratory allegedly paid kickbacks and billed Medicare and Medicaid for medically unnecessary genetic tests. The settlements with the laboratory and other parties add up to 36.4 million USD (combined total); the laboratory is subject to a Corporate Integrity Agreement.
Commission models for intermediaries who bring in orders or patients are a classic gateway for bribery.
Remuneration of intermediaries and referrers
- Authority / court
- U.S. Department of Justice
- Area of law
- Bribery and corruption · Commercial bribery
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Healthcare
- Liability of senior managers
- Measures against individuals are not reported here.
Original amount 36,400,000 USD, converted at the ECB reference rate of 30 Jul 2026.
- HHS-OIG Enforcement Actions: Vergleiche mit Access DX Laboratory und weiteren Beteiligten (30.07.2026) Enforcement database of an authority
Checked against the official source on 28 Sep 2026 · Version 3 · Direct link